The choice of either induction or postremission therapy for adults with acute myeloid
leukemia is still largely based on the “one size fits all” principle. Moreover, pretreatment …

Technological advances in the laboratory have led to substantial improvements in clinical
decision making through the introduction of pretreatment prognostic risk stratification factors …

Relapse is a major problem in acute myeloid leukemia (AML) and adversely affects survival.
In this phase 2 study, we investigated the effect of vaccination with dendritic cells (DCs) …

Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on
pretreatment characteristics. It remains to be established whether relapse risk can be better …

Active immunization using tumor antigen-loaded dendritic cells holds promise for the
adjuvant treatment of cancer to eradicate or control residual disease, but so far, most …

As relapses are common in acute myeloid leukemia (AML), early relapse prediction is of
high importance. Although conventional minimal residual disease (MRD) measurement is …

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients
and is influenced by gemtuzumab ozogamicin - PMC Back to Top Skip to main content NIH …

Several disease-monitoring techniques are available for the physician treating acute
myeloid leukaemia (AML). Besides immunohistochemistry assisted light microscopy, the …

Relapse of malignant disease remains the major complication in patients with acute myeloid
leukemia (AML) or myelodysplastic syndrome (MDS) after hematopoietic cell transplantation …

We retrospectively assessed whether normalized bone marrow WT1 levels could be used
for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A …